



2nd ALIPANC Scientific Meeting

9:15 – 9:30 Registration and welcome

9:30 - 10:15 Keynote: (Chair: Pancho Barriga).

Peter Bailey, PhD (Director of Translational Research, Botton Champalimaud Pancreatic Cancer Center). **“Pancreatic Cancer and the role of extrachromosomal DNA”**

10:15 – 11:15 Session 1: Chair: Meritxell Rovira.

10:15 – 10:35 Elisa Espinet (Group Leader, UB). **“Pancreatic ductal adenocarcinoma, a heterogeneous disease from a two-compartment point of view”**

10:35 – 10:55 Cristina Fillat (Group Leader, IDIBAPS). **“Deciphering the role of DYRK1A in PDAC”**

10:55 – 11:15 Giuseppe Diaferia (Group Leader, Botton Champalimaud Pancreatic Cancer Center). **“Histologically Resolved Transcriptional States Unveil Functional Vulnerabilities in PDAC”**

11:15 – 12:00 Networking (Tian Tian) + coffee break 1

12:00 – 13:00 Session 2: Chair: Elisa Espinet.

12:00 – 12:20 Shruthi Narayan (PhD student, CIMA). **“Exploiting the LAMC2-driven signaling network to identify effective combination therapies for pancreatic cancer.”**

12:20 – 12:40 Isabel Villaoslada (PhD student, IIS / Aragon). **“PDXO-on-chip: a novel approach for studying mechanical properties on pancreatic ductal adenocarcinoma”**

12:40 – 13:00 Natalia Tissera (PhD student, VHIO). **“Current State of the Art of KRAS Inhibitors in PDAC Treatment”**

13:00 – 13:45 Lunch + poster session

13:45 – 15:00 Poster Session

15:00 – 15:05 Working Groups (Raquel Benitez and Irene Felipe)

15:05 – 15:15 Homenaje Familia Mora

15:15 – 16:15 Session 3 (Chair: Patricia Sancho).

15:15 – 15:35 Meritxell Rovira, PhD (Group Leader, UB). **“Are pancreatic ducts anything more than pipes?”**

15:35 – 15:55 Yurena Vivas (Postdoc, CNIO) **“Myeloid nutrient signalling drives paracrine acinar inflammation and boosts pancreas cancer”**.

15:55 – 16:15 Evangelina López de Maturana (Staff Scientist, CNIO). **“Multimodal machine learning-based integration of genomics, radiomics, and pathomics prognostic scores improves pancreatic ductal adenocarcinoma clinical-based patient stratification”**

16:15 – 17:00 Coffee break 2 + Networking event

17:00 – 17:45 Keynote (Chair: Tian Tian).

Joaquin Arribas, PhD (Director of HMRI, Barcelona). **“Immune redirection against HER2-Positive Tumors: From Breast to Pancreas”**

This event has been partially funded by:

novocure®

SERVIER
moved by you



ALIPANC maintains its independency and full autonomy in its development and organization.



Posters

Poster 1: Beatriz Alonso Parejo. Serine and Glycine Deprivation Promote Stemness-Related Features in Pancreatic Cancer Cells.

Poster 2: Neus Martinez Bosch. PARP2 selective inhibition impairs pancreatic cancer progression by promoting genomic instability and anti-tumor immunity.

Poster 3: Nuria Vázquez Bellón. Characterization of Tumor-Associated Glycosylation in Pancreatic Cancer.

Poster 4: Adrián Santiso. Generation of Pancreatic Ductal Adenocarcinoma Pathological (PDAC) Images from RNA sequencing data using deep learning models.

Poster 5: Alejandra González Loyola. Novel PDAC on a chip model as preclinical in vitro platform.

Poster 6: Gabriela Novoa Jaso. In vivo CRISPR/Cas9-based functional screen to identify tumor microenvironment sensitizers to KRAS inhibition in Pancreatic Cancer.

Poster 7: Mikhail Chesnokov. Gata4 deficiency establishes a PanIN-less route to pancreatic ductal adenocarcinoma.

Poster 8: Paula Morales Sánchez. Overcoming Chemotherapy-Induced Apoptotic Resistance in Pancreatic Cancer.

Poster 9: Alba Royo García. Crosstalk between adipocytes and cancer stem cells promotes aggressiveness in pancreatic cancer.

Poster 10: Francesca Pontis. SEMA3C isoforms distinctly affect fibroblast activity in fibrosis and cancer progression.

Poster 11: Jose María Herranz Alzueta. Enhancing treatment response prediction in PDAC patients with data augmentation coupled to deep learning environments.

Poster 12: Sofia Llorente Llorente. A collection of patient-derived xenograft models for pancreatic ductal adenocarcinoma translational research.

Poster 13: Ariel Acuña Pincay. The crosstalk between CAFs and tumor cells: a pathway to pancreatic cancer progression.

Poster 14: Martín Jimenez Arriola. Establishing a Primary Human CAF Collection: A Powerful Resource for Functional Studies in Tumor-Stroma Interactions in Pancreatic Cancer

Poster 15: Nicolás Peláez Llana. Cell of origin of pancreatic cancer: deciphering cancer's heterogeneity to better understanding diagnosis and treatment.

Poster 16: Dario Ruiz Ciano. Deciphering the role of copy number alterations in PDAC immune evasion.

This event has been partially funded by:

novocure®

SERVIER
moved by you



ALIPANC maintains its independency and full autonomy in its development and organization.